The PRNewswire-announced transaction includes $125 million upfront and another $125 million in Q1 2027, with the balance tied to clinical and regulatory milestones as Neurimmune funds internal R&D.
Neurimmune said it sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront, giving the clinical-stage biopharmaceutical company non-dilutive funding for its research pipeline. Under the agreement, Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales of cliramitug, while Neurimmune said it will retain substantial portions of its royalty and milestone interest in the drug. The deal also includes another $125 million cash payment in the first quarter of 2027, with the remaining $175 million contingent on specified clinical and regulatory milestones. Cliramitug, formerly NI006 and ALXN2220, is an investigational human monoclonal antibody designed to clear amyloid deposits from the hearts of patients with ATTR-CM (a heart disease caused by transthyretin amyloid buildup). Neurimmune licensed the program in 2022 to Alexion, AstraZeneca Rare Disease, which is handling development, manufacturing and commercialization, including the ongoing DepleTTR-CM Phase 3 trial.